 | • レポートコード：MRC2-11QY02523 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は抗体薬物複合体のグローバル市場について調査・分析したレポートです。種類別（アドセトリス、カドシル、その他）市場規模、用途別（病院、製薬会社、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別抗体薬物複合体の競争状況、市場シェア ・世界の抗体薬物複合体市場：種類別市場規模 2015年-2020年（アドセトリス、カドシル、その他） ・世界の抗体薬物複合体市場：種類別市場規模予測 2021年-2026年（アドセトリス、カドシル、その他） ・世界の抗体薬物複合体市場：用途別市場規模 2015年-2020年（病院、製薬会社、研究機関） ・世界の抗体薬物複合体市場：用途別市場規模予測 2021年-2026年（病院、製薬会社、研究機関） ・北米の抗体薬物複合体市場分析：米国、カナダ ・ヨーロッパの抗体薬物複合体市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの抗体薬物複合体市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の抗体薬物複合体市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの抗体薬物複合体市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Seattle Genetics/Takeda、Roche、ImmunoGen、Immunomedics、Pfizer、Celldex Therapeutics、Millennium Pharmaceuticals、Bayer HealthCare、Mersana Therapeutics、Heidelberg Pharma、Oxford BioTherapeutics、Takeda Pharmaceutical Company Limited ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Antibody Drug Conjugate Market
The global Antibody Drug Conjugate market size is projected to reach US$ 1831.1 million by 2026, from US$ 1696.9 million in 2020, at a CAGR of 7.3%% during 2021-2026.
Global Antibody Drug Conjugate Scope and Market Size
Antibody Drug Conjugate market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Antibody Drug Conjugate market is segmented into
Adcetris
Kadcyl
Other
Segment by Application, the Antibody Drug Conjugate market is segmented into
Hospital
Pharmaceutical Company
Research Institutions
Regional and Country-level Analysis
The Antibody Drug Conjugate market is analysed and market size information is provided by regions (countries).
The key regions covered in the Antibody Drug Conjugate market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Antibody Drug Conjugate Market Share Analysis
Antibody Drug Conjugate market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Antibody Drug Conjugate business, the date to enter into the Antibody Drug Conjugate market, Antibody Drug Conjugate product introduction, recent developments, etc.
The major vendors covered:
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
1 Study Coverage
1.1 Antibody Drug Conjugate Product Introduction
1.2 Market Segments
1.3 Key Antibody Drug Conjugate Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Antibody Drug Conjugate Market Size Growth Rate by Type
1.4.2 Adcetris
1.4.3 Kadcyl
1.4.4 Other
1.5 Market by Application
1.5.1 Global Antibody Drug Conjugate Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Pharmaceutical Company
1.5.4 Research Institutions
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Antibody Drug Conjugate Market Size, Estimates and Forecasts
2.1.1 Global Antibody Drug Conjugate Revenue 2015-2026
2.1.2 Global Antibody Drug Conjugate Sales 2015-2026
2.2 Global Antibody Drug Conjugate, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Antibody Drug Conjugate Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Antibody Drug Conjugate Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Antibody Drug Conjugate Competitor Landscape by Players
3.1 Antibody Drug Conjugate Sales by Manufacturers
3.1.1 Antibody Drug Conjugate Sales by Manufacturers (2015-2020)
3.1.2 Antibody Drug Conjugate Sales Market Share by Manufacturers (2015-2020)
3.2 Antibody Drug Conjugate Revenue by Manufacturers
3.2.1 Antibody Drug Conjugate Revenue by Manufacturers (2015-2020)
3.2.2 Antibody Drug Conjugate Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Antibody Drug Conjugate Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate Revenue in 2019
3.2.5 Global Antibody Drug Conjugate Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Antibody Drug Conjugate Price by Manufacturers
3.4 Antibody Drug Conjugate Manufacturing Base Distribution, Product Types
3.4.1 Antibody Drug Conjugate Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Antibody Drug Conjugate Product Type
3.4.3 Date of International Manufacturers Enter into Antibody Drug Conjugate Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Antibody Drug Conjugate Market Size by Type (2015-2020)
4.1.1 Global Antibody Drug Conjugate Sales by Type (2015-2020)
4.1.2 Global Antibody Drug Conjugate Revenue by Type (2015-2020)
4.1.3 Antibody Drug Conjugate Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Antibody Drug Conjugate Market Size Forecast by Type (2021-2026)
4.2.1 Global Antibody Drug Conjugate Sales Forecast by Type (2021-2026)
4.2.2 Global Antibody Drug Conjugate Revenue Forecast by Type (2021-2026)
4.2.3 Antibody Drug Conjugate Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Antibody Drug Conjugate Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Antibody Drug Conjugate Market Size by Application (2015-2020)
5.1.1 Global Antibody Drug Conjugate Sales by Application (2015-2020)
5.1.2 Global Antibody Drug Conjugate Revenue by Application (2015-2020)
5.1.3 Antibody Drug Conjugate Price by Application (2015-2020)
5.2 Antibody Drug Conjugate Market Size Forecast by Application (2021-2026)
5.2.1 Global Antibody Drug Conjugate Sales Forecast by Application (2021-2026)
5.2.2 Global Antibody Drug Conjugate Revenue Forecast by Application (2021-2026)
5.2.3 Global Antibody Drug Conjugate Price Forecast by Application (2021-2026)
6 North America
6.1 North America Antibody Drug Conjugate by Country
6.1.1 North America Antibody Drug Conjugate Sales by Country
6.1.2 North America Antibody Drug Conjugate Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Antibody Drug Conjugate Market Facts & Figures by Type
6.3 North America Antibody Drug Conjugate Market Facts & Figures by Application
7 Europe
7.1 Europe Antibody Drug Conjugate by Country
7.1.1 Europe Antibody Drug Conjugate Sales by Country
7.1.2 Europe Antibody Drug Conjugate Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Antibody Drug Conjugate Market Facts & Figures by Type
7.3 Europe Antibody Drug Conjugate Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Antibody Drug Conjugate by Region
8.1.1 Asia Pacific Antibody Drug Conjugate Sales by Region
8.1.2 Asia Pacific Antibody Drug Conjugate Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Antibody Drug Conjugate Market Facts & Figures by Type
8.3 Asia Pacific Antibody Drug Conjugate Market Facts & Figures by Application
9 Latin America
9.1 Latin America Antibody Drug Conjugate by Country
9.1.1 Latin America Antibody Drug Conjugate Sales by Country
9.1.2 Latin America Antibody Drug Conjugate Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Antibody Drug Conjugate Market Facts & Figures by Type
9.3 Central & South America Antibody Drug Conjugate Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Antibody Drug Conjugate by Country
10.1.1 Middle East and Africa Antibody Drug Conjugate Sales by Country
10.1.2 Middle East and Africa Antibody Drug Conjugate Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Antibody Drug Conjugate Market Facts & Figures by Type
10.3 Middle East and Africa Antibody Drug Conjugate Market Facts & Figures by Application
11 Company Profiles
11.1 Seattle Genetics/Takeda
11.1.1 Seattle Genetics/Takeda Corporation Information
11.1.2 Seattle Genetics/Takeda Description and Business Overview
11.1.3 Seattle Genetics/Takeda Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Seattle Genetics/Takeda Antibody Drug Conjugate Products Offered
11.1.5 Seattle Genetics/Takeda Related Developments
11.2 Roche
11.2.1 Roche Corporation Information
11.2.2 Roche Description and Business Overview
11.2.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Roche Antibody Drug Conjugate Products Offered
11.2.5 Roche Related Developments
11.3 ImmunoGen
11.3.1 ImmunoGen Corporation Information
11.3.2 ImmunoGen Description and Business Overview
11.3.3 ImmunoGen Sales, Revenue and Gross Margin (2015-2020)
11.3.4 ImmunoGen Antibody Drug Conjugate Products Offered
11.3.5 ImmunoGen Related Developments
11.4 Immunomedics
11.4.1 Immunomedics Corporation Information
11.4.2 Immunomedics Description and Business Overview
11.4.3 Immunomedics Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Immunomedics Antibody Drug Conjugate Products Offered
11.4.5 Immunomedics Related Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Description and Business Overview
11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Antibody Drug Conjugate Products Offered
11.5.5 Pfizer Related Developments
11.6 Celldex Therapeutics
11.6.1 Celldex Therapeutics Corporation Information
11.6.2 Celldex Therapeutics Description and Business Overview
11.6.3 Celldex Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Celldex Therapeutics Antibody Drug Conjugate Products Offered
11.6.5 Celldex Therapeutics Related Developments
11.7 Millennium Pharmaceuticals
11.7.1 Millennium Pharmaceuticals Corporation Information
11.7.2 Millennium Pharmaceuticals Description and Business Overview
11.7.3 Millennium Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Millennium Pharmaceuticals Antibody Drug Conjugate Products Offered
11.7.5 Millennium Pharmaceuticals Related Developments
11.8 Bayer HealthCare
11.8.1 Bayer HealthCare Corporation Information
11.8.2 Bayer HealthCare Description and Business Overview
11.8.3 Bayer HealthCare Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Bayer HealthCare Antibody Drug Conjugate Products Offered
11.8.5 Bayer HealthCare Related Developments
11.9 Mersana Therapeutics
11.9.1 Mersana Therapeutics Corporation Information
11.9.2 Mersana Therapeutics Description and Business Overview
11.9.3 Mersana Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Mersana Therapeutics Antibody Drug Conjugate Products Offered
11.9.5 Mersana Therapeutics Related Developments
11.10 Heidelberg Pharma
11.10.1 Heidelberg Pharma Corporation Information
11.10.2 Heidelberg Pharma Description and Business Overview
11.10.3 Heidelberg Pharma Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Heidelberg Pharma Antibody Drug Conjugate Products Offered
11.10.5 Heidelberg Pharma Related Developments
11.1 Seattle Genetics/Takeda
11.1.1 Seattle Genetics/Takeda Corporation Information
11.1.2 Seattle Genetics/Takeda Description and Business Overview
11.1.3 Seattle Genetics/Takeda Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Seattle Genetics/Takeda Antibody Drug Conjugate Products Offered
11.1.5 Seattle Genetics/Takeda Related Developments
11.12 Takeda Pharmaceutical Company Limited
11.12.1 Takeda Pharmaceutical Company Limited Corporation Information
11.12.2 Takeda Pharmaceutical Company Limited Description and Business Overview
11.12.3 Takeda Pharmaceutical Company Limited Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Takeda Pharmaceutical Company Limited Products Offered
11.12.5 Takeda Pharmaceutical Company Limited Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Antibody Drug Conjugate Market Estimates and Projections by Region
12.1.1 Global Antibody Drug Conjugate Sales Forecast by Regions 2021-2026
12.1.2 Global Antibody Drug Conjugate Revenue Forecast by Regions 2021-2026
12.2 North America Antibody Drug Conjugate Market Size Forecast (2021-2026)
12.2.1 North America: Antibody Drug Conjugate Sales Forecast (2021-2026)
12.2.2 North America: Antibody Drug Conjugate Revenue Forecast (2021-2026)
12.2.3 North America: Antibody Drug Conjugate Market Size Forecast by Country (2021-2026)
12.3 Europe Antibody Drug Conjugate Market Size Forecast (2021-2026)
12.3.1 Europe: Antibody Drug Conjugate Sales Forecast (2021-2026)
12.3.2 Europe: Antibody Drug Conjugate Revenue Forecast (2021-2026)
12.3.3 Europe: Antibody Drug Conjugate Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Antibody Drug Conjugate Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Antibody Drug Conjugate Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Antibody Drug Conjugate Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Antibody Drug Conjugate Market Size Forecast by Region (2021-2026)
12.5 Latin America Antibody Drug Conjugate Market Size Forecast (2021-2026)
12.5.1 Latin America: Antibody Drug Conjugate Sales Forecast (2021-2026)
12.5.2 Latin America: Antibody Drug Conjugate Revenue Forecast (2021-2026)
12.5.3 Latin America: Antibody Drug Conjugate Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Antibody Drug Conjugate Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Antibody Drug Conjugate Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Antibody Drug Conjugate Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Antibody Drug Conjugate Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Antibody Drug Conjugate Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Antibody Drug Conjugate Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Antibody Drug Conjugate Market Segments
Table 2. Ranking of Global Top Antibody Drug Conjugate Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Antibody Drug Conjugate Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Adcetris
Table 5. Major Manufacturers of Kadcyl
Table 6. Major Manufacturers of Other
Table 7. Global Antibody Drug Conjugate Market Size Growth Rate by Application 2020-2026 (K Units)
Table 8. Global Antibody Drug Conjugate Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 9. Global Antibody Drug Conjugate Sales by Regions 2015-2020 (K Units)
Table 10. Global Antibody Drug Conjugate Sales Market Share by Regions (2015-2020)
Table 11. Global Antibody Drug Conjugate Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Antibody Drug Conjugate Sales by Manufacturers (2015-2020) (K Units)
Table 13. Global Antibody Drug Conjugate Sales Share by Manufacturers (2015-2020)
Table 14. Global Antibody Drug Conjugate Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Antibody Drug Conjugate by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugate as of 2019)
Table 16. Antibody Drug Conjugate Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Antibody Drug Conjugate Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Antibody Drug Conjugate Price (2015-2020) (USD/Unit)
Table 19. Antibody Drug Conjugate Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Antibody Drug Conjugate Product Type
Table 21. Date of International Manufacturers Enter into Antibody Drug Conjugate Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody Drug Conjugate Sales by Type (2015-2020) (K Units)
Table 24. Global Antibody Drug Conjugate Sales Share by Type (2015-2020)
Table 25. Global Antibody Drug Conjugate Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Antibody Drug Conjugate Revenue Share by Type (2015-2020)
Table 27. Antibody Drug Conjugate Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 28. Global Antibody Drug Conjugate Sales by Application (2015-2020) (K Units)
Table 29. Global Antibody Drug Conjugate Sales Share by Application (2015-2020)
Table 30. North America Antibody Drug Conjugate Sales by Country (2015-2020) (K Units)
Table 31. North America Antibody Drug Conjugate Sales Market Share by Country (2015-2020)
Table 32. North America Antibody Drug Conjugate Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Antibody Drug Conjugate Revenue Market Share by Country (2015-2020)
Table 34. North America Antibody Drug Conjugate Sales by Type (2015-2020) (K Units)
Table 35. North America Antibody Drug Conjugate Sales Market Share by Type (2015-2020)
Table 36. North America Antibody Drug Conjugate Sales by Application (2015-2020) (K Units)
Table 37. North America Antibody Drug Conjugate Sales Market Share by Application (2015-2020)
Table 38. Europe Antibody Drug Conjugate Sales by Country (2015-2020) (K Units)
Table 39. Europe Antibody Drug Conjugate Sales Market Share by Country (2015-2020)
Table 40. Europe Antibody Drug Conjugate Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Antibody Drug Conjugate Revenue Market Share by Country (2015-2020)
Table 42. Europe Antibody Drug Conjugate Sales by Type (2015-2020) (K Units)
Table 43. Europe Antibody Drug Conjugate Sales Market Share by Type (2015-2020)
Table 44. Europe Antibody Drug Conjugate Sales by Application (2015-2020) (K Units)
Table 45. Europe Antibody Drug Conjugate Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Antibody Drug Conjugate Sales by Region (2015-2020) (K Units)
Table 47. Asia Pacific Antibody Drug Conjugate Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Antibody Drug Conjugate Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Antibody Drug Conjugate Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Antibody Drug Conjugate Sales by Type (2015-2020) (K Units)
Table 51. Asia Pacific Antibody Drug Conjugate Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Antibody Drug Conjugate Sales by Application (2015-2020) (K Units)
Table 53. Asia Pacific Antibody Drug Conjugate Sales Market Share by Application (2015-2020)
Table 54. Latin America Antibody Drug Conjugate Sales by Country (2015-2020) (K Units)
Table 55. Latin America Antibody Drug Conjugate Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Antibody Drug Conjugate Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Antibody Drug Conjugate Revenue Market Share by Country (2015-2020)
Table 58. Latin America Antibody Drug Conjugate Sales by Type (2015-2020) (K Units)
Table 59. Latin America Antibody Drug Conjugate Sales Market Share by Type (2015-2020)
Table 60. Latin America Antibody Drug Conjugate Sales by Application (2015-2020) (K Units)
Table 61. Latin America Antibody Drug Conjugate Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Antibody Drug Conjugate Sales by Country (2015-2020) (K Units)
Table 63. Middle East and Africa Antibody Drug Conjugate Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Antibody Drug Conjugate Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Antibody Drug Conjugate Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Antibody Drug Conjugate Sales by Type (2015-2020) (K Units)
Table 67. Middle East and Africa Antibody Drug Conjugate Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Antibody Drug Conjugate Sales by Application (2015-2020) (K Units)
Table 69. Middle East and Africa Antibody Drug Conjugate Sales Market Share by Application (2015-2020)
Table 70. Seattle Genetics/Takeda Corporation Information
Table 71. Seattle Genetics/Takeda Description and Major Businesses
Table 72. Seattle Genetics/Takeda Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 73. Seattle Genetics/Takeda Product
Table 74. Seattle Genetics/Takeda Recent Development
Table 75. Roche Corporation Information
Table 76. Roche Description and Major Businesses
Table 77. Roche Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 78. Roche Product
Table 79. Roche Recent Development
Table 80. ImmunoGen Corporation Information
Table 81. ImmunoGen Description and Major Businesses
Table 82. ImmunoGen Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 83. ImmunoGen Product
Table 84. ImmunoGen Recent Development
Table 85. Immunomedics Corporation Information
Table 86. Immunomedics Description and Major Businesses
Table 87. Immunomedics Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 88. Immunomedics Product
Table 89. Immunomedics Recent Development
Table 90. Pfizer Corporation Information
Table 91. Pfizer Description and Major Businesses
Table 92. Pfizer Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 93. Pfizer Product
Table 94. Pfizer Recent Development
Table 95. Celldex Therapeutics Corporation Information
Table 96. Celldex Therapeutics Description and Major Businesses
Table 97. Celldex Therapeutics Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 98. Celldex Therapeutics Product
Table 99. Celldex Therapeutics Recent Development
Table 100. Millennium Pharmaceuticals Corporation Information
Table 101. Millennium Pharmaceuticals Description and Major Businesses
Table 102. Millennium Pharmaceuticals Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 103. Millennium Pharmaceuticals Product
Table 104. Millennium Pharmaceuticals Recent Development
Table 105. Bayer HealthCare Corporation Information
Table 106. Bayer HealthCare Description and Major Businesses
Table 107. Bayer HealthCare Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 108. Bayer HealthCare Product
Table 109. Bayer HealthCare Recent Development
Table 110. Mersana Therapeutics Corporation Information
Table 111. Mersana Therapeutics Description and Major Businesses
Table 112. Mersana Therapeutics Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 113. Mersana Therapeutics Product
Table 114. Mersana Therapeutics Recent Development
Table 115. Heidelberg Pharma Corporation Information
Table 116. Heidelberg Pharma Description and Major Businesses
Table 117. Heidelberg Pharma Antibody Drug Conjugate Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 118. Heidelberg Pharma Product
Table 119. Heidelberg Pharma Recent Development
Table 120. Oxford BioTherapeutics Corporation Information
Table 121. Oxford BioTherapeutics Description and Major Businesses
Table 122. Oxford BioTherapeutics Antibody Drug Conjugate Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 123. Oxford BioTherapeutics Product
Table 124. Oxford BioTherapeutics Recent Development
Table 125. Takeda Pharmaceutical Company Limited Corporation Information
Table 126. Takeda Pharmaceutical Company Limited Description and Major Businesses
Table 127. Takeda Pharmaceutical Company Limited Antibody Drug Conjugate Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 128. Takeda Pharmaceutical Company Limited Product
Table 129. Takeda Pharmaceutical Company Limited Recent Development
Table 130. Global Antibody Drug Conjugate Sales Forecast by Regions (2021-2026) (K Units)
Table 131. Global Antibody Drug Conjugate Sales Market Share Forecast by Regions (2021-2026)
Table 132. Global Antibody Drug Conjugate Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 133. Global Antibody Drug Conjugate Revenue Market Share Forecast by Regions (2021-2026)
Table 134. North America: Antibody Drug Conjugate Sales Forecast by Country (2021-2026) (K Units)
Table 135. North America: Antibody Drug Conjugate Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Europe: Antibody Drug Conjugate Sales Forecast by Country (2021-2026) (K Units)
Table 137. Europe: Antibody Drug Conjugate Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Asia Pacific: Antibody Drug Conjugate Sales Forecast by Region (2021-2026) (K Units)
Table 139. Asia Pacific: Antibody Drug Conjugate Revenue Forecast by Region (2021-2026) (US$ Million)
Table 140. Latin America: Antibody Drug Conjugate Sales Forecast by Country (2021-2026) (K Units)
Table 141. Latin America: Antibody Drug Conjugate Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Middle East and Africa: Antibody Drug Conjugate Sales Forecast by Country (2021-2026) (K Units)
Table 143. Middle East and Africa: Antibody Drug Conjugate Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 145. Key Challenges
Table 146. Market Risks
Table 147. Main Points Interviewed from Key Antibody Drug Conjugate Players
Table 148. Antibody Drug Conjugate Customers List
Table 149. Antibody Drug Conjugate Distributors List
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibody Drug Conjugate Product Picture
Figure 2. Global Antibody Drug Conjugate Sales Market Share by Type in 2020 & 2026
Figure 3. Adcetris Product Picture
Figure 4. Kadcyl Product Picture
Figure 5. Other Product Picture
Figure 6. Global Antibody Drug Conjugate Sales Market Share by Application in 2020 & 2026
Figure 7. Hospital
Figure 8. Pharmaceutical Company
Figure 9. Research Institutions
Figure 10. Antibody Drug Conjugate Report Years Considered
Figure 11. Global Antibody Drug Conjugate Market Size 2015-2026 (US$ Million)
Figure 12. Global Antibody Drug Conjugate Sales 2015-2026 (K Units)
Figure 13. Global Antibody Drug Conjugate Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Antibody Drug Conjugate Sales Market Share by Region (2015-2020)
Figure 15. Global Antibody Drug Conjugate Sales Market Share by Region in 2019
Figure 16. Global Antibody Drug Conjugate Revenue Market Share by Region (2015-2020)
Figure 17. Global Antibody Drug Conjugate Revenue Market Share by Region in 2019
Figure 18. Global Antibody Drug Conjugate Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate Revenue in 2019
Figure 20. Antibody Drug Conjugate Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Antibody Drug Conjugate Sales Market Share by Type (2015-2020)
Figure 22. Global Antibody Drug Conjugate Sales Market Share by Type in 2019
Figure 23. Global Antibody Drug Conjugate Revenue Market Share by Type (2015-2020)
Figure 24. Global Antibody Drug Conjugate Revenue Market Share by Type in 2019
Figure 25. Global Antibody Drug Conjugate Market Share by Price Range (2015-2020)
Figure 26. Global Antibody Drug Conjugate Sales Market Share by Application (2015-2020)
Figure 27. Global Antibody Drug Conjugate Sales Market Share by Application in 2019
Figure 28. Global Antibody Drug Conjugate Revenue Market Share by Application (2015-2020)
Figure 29. Global Antibody Drug Conjugate Revenue Market Share by Application in 2019
Figure 30. North America Antibody Drug Conjugate Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Antibody Drug Conjugate Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Antibody Drug Conjugate Sales Market Share by Country in 2019
Figure 33. North America Antibody Drug Conjugate Revenue Market Share by Country in 2019
Figure 34. U.S. Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Antibody Drug Conjugate Market Share by Type in 2019
Figure 39. North America Antibody Drug Conjugate Market Share by Application in 2019
Figure 40. Europe Antibody Drug Conjugate Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Antibody Drug Conjugate Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Antibody Drug Conjugate Sales Market Share by Country in 2019
Figure 43. Europe Antibody Drug Conjugate Revenue Market Share by Country in 2019
Figure 44. Germany Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Antibody Drug Conjugate Market Share by Type in 2019
Figure 55. Europe Antibody Drug Conjugate Market Share by Application in 2019
Figure 56. Asia Pacific Antibody Drug Conjugate Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Antibody Drug Conjugate Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Antibody Drug Conjugate Sales Market Share by Region in 2019
Figure 59. Asia Pacific Antibody Drug Conjugate Revenue Market Share by Region in 2019
Figure 60. China Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Antibody Drug Conjugate Market Share by Type in 2019
Figure 83. Asia Pacific Antibody Drug Conjugate Market Share by Application in 2019
Figure 84. Latin America Antibody Drug Conjugate Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Antibody Drug Conjugate Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Antibody Drug Conjugate Sales Market Share by Country in 2019
Figure 87. Latin America Antibody Drug Conjugate Revenue Market Share by Country in 2019
Figure 88. Mexico Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Antibody Drug Conjugate Market Share by Type in 2019
Figure 95. Latin America Antibody Drug Conjugate Market Share by Application in 2019
Figure 96. Middle East and Africa Antibody Drug Conjugate Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Antibody Drug Conjugate Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Antibody Drug Conjugate Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Antibody Drug Conjugate Revenue Market Share by Country in 2019
Figure 100. Turkey Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Antibody Drug Conjugate Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Antibody Drug Conjugate Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Antibody Drug Conjugate Market Share by Type in 2019
Figure 107. Middle East and Africa Antibody Drug Conjugate Market Share by Application in 2019
Figure 108. North America Antibody Drug Conjugate Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Antibody Drug Conjugate Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Antibody Drug Conjugate Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Antibody Drug Conjugate Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Antibody Drug Conjugate Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Antibody Drug Conjugate Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Antibody Drug Conjugate Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Antibody Drug Conjugate Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Antibody Drug Conjugate Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Antibody Drug Conjugate Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
抗体薬物複合体（ADC）の世界市場（～2026年） Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased…- 髄膜炎菌コンジュゲートの世界市場（～2026年） Meningococcal disease can become life threatening quickly, and teens are at higher risk of getting it. It's a leading cause of bacterial meningitis in teens. Meningitis is a dangerous inflammation of the lining of the brain and spinal cord. Two meningitis vaccines protects against four types of meni…
- モノクローナル抗体療法の世界市場（～2026年） Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal ant…
- 次世代抗体療法の世界市場（～2026年） The ADCs segment held the largest market share in the historical period and is projected to hold a market share of over 50% by 2025. The Fc engineered antibodies segmented is projected to witness the fastest growth during the forecast period. Market Analysis and Insights: Global Next Generation Anti…
- モノクローナル抗体ベース製品の世界市場（～2026年） Monoclonal antibody therapeutics is a type of immunotherapy in which monoclonal antibodies are used so that they can bind monospecifically to specific cells and proteins. This treatment stimulates the immune system of patients to attack the foreign cells which cause the disease. Monoclonal antibodie…